A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia

Inhibition of farnesyltransferase (FT) activity has been associated with in vitro and in vivo anti-leukemia activity. We report the results of a phase 1 dose escalation study of tipifarnib, an oral FT inhibitor, in patients with relapsed, refractory, or newly diagnosed (if over age 70) acute myeloge...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirschbaum, Mark, Synold, Timothy, Stein, Anthony S., Tuscano, Joseph, Zain, Jasmine M., Popplewell, Leslie, Karanes, Chatchada, O'Donnell, Margaret R., Pulone, Bernadette, Rincon, Amalia, Wright, John, Frankel, Paul, Forman, Stephen J., Newman, Edward M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165084/
https://www.ncbi.nlm.nih.gov/pubmed/21625235
http://dx.doi.org/10.1038/leu.2011.124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165084/
https://www.ncbi.nlm.nih.gov/pubmed/21625235
http://dx.doi.org/10.1038/leu.2011.124

Ejemplares similares